Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IFRX.”

Based in Jena, Germany, InflaRx develops new first-in-class therapeutics targeting acute and chronic inflammation. Its primary focus is on the development of monoclonal antibodies that target activation products of the complement system for application in life-threatening inflammatory diseases.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate David Li. The tax team included partner Mario J. Verdolini and associate Danielle Rapaccioli. The intellectual property and technology transactions team included partner David R. Bauer and associate Hilary Smith. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post